735 related articles for article (PubMed ID: 34781066)
21. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
[No Abstract] [Full Text] [Related]
22. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
[No Abstract] [Full Text] [Related]
23. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
24. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Gaballa MR; Ma J; Rauf M; Bassett R; Pasvolsky O; Tanner MR; Bashir Q; Srour SA; Saini N; Ramdial J; Nieto Y; Murphy R; Rezvani K; Tang G; Lin P; Lee HC; Patel KK; Ullah MR; Kaufman GP; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Shpall EJ; Champlin RE; Orlowski RZ; Qazilbash MH
Bone Marrow Transplant; 2022 Jul; 57(7):1142-1149. PubMed ID: 35523847
[TBL] [Abstract][Full Text] [Related]
25. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
Gaballa MR; Ma J; Tanner MR; Al-Juhaishi T; Bashir Q; Srour SA; Saini NY; Ramdial JL; Nieto Y; Murphy R; Rezvani K; Tang G; Lee HC; Patel KK; Kaufman GP; Manasanch EE; Ullah MR; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2022 Mar; 63(3):710-721. PubMed ID: 34686083
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
28. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
29. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update.
Bazarbachi AH; Al Hamed R; Malard F; Bazarbachi A; Harousseau JL; Mohty M
Blood Cancer J; 2022 Mar; 12(3):47. PubMed ID: 35347107
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR; Derkach A; Nemirovsky D; Ciardiello A; Diamond B; Hultcrantz M; Hassoun H; Mailankody S; Shah U; Maclachlan K; Patel D; Lahoud OB; Landau HJ; Chung DJ; Shah GL; Scordo M; Giralt SA; Lesokhin A; Usmani SZ; Landgren O; Korde N
Blood Cancer J; 2023 Jul; 13(1):112. PubMed ID: 37491332
[TBL] [Abstract][Full Text] [Related]
33. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J
Blood; 2019 Oct; 134(16):1337-1345. PubMed ID: 31484647
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P
Leukemia; 2023 Jul; 37(7):1521-1529. PubMed ID: 37316728
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
37. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.
Zhou Q; Xu F; Wen J; Yue J; Zhang Y; Su J; Liu Y
Clin Exp Med; 2023 Sep; 23(5):1573-1580. PubMed ID: 36094683
[TBL] [Abstract][Full Text] [Related]
39. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
[TBL] [Abstract][Full Text] [Related]
40. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]